Navigation Links
HemoShear to Develop Human Cancer Models to Improve Industry Success Rates in New Anticancer Drug Development
Date:11/7/2013

CHARLOTTESVILLE, Va., Nov. 7, 2013 /PRNewswire/ -- Safer and more effective anticancer drugs may soon be developed thanks to a Small Business Innovation Research contract recently awarded to HemoShear by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH).  HemoShear, LLC, is the pharmaceutical industry's leading developer of the most advanced human biology systems for applications in drug research and development. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO)

Anticancer drugs continue to suffer the highest rate of failure in clinical trials as compared with other therapeutic areas.  According to the NCI, "There is a critical need to improve the accuracy of preclinical drug efficacy screening and testing through the development of [laboratory-based] culture systems that more effectively mimic the [human] environment.  Systems to properly recreate the tumor microenvironment are lacking and [are] essential to advance the discovery and development of effective anticancer agents."

HemoShear's contract with the National Cancer Institute will support the development of human cell-based systems that accurately replicate the biology of lung and pancreatic tumors, two of the deadliest groups of tumors.  "Lung and pancreatic cancer are terrible diseases that have no effective treatments," said Dr. Brian Wamhoff, HemoShear co-founder and Vice President of R&D.  "We are using our innovative science to enable the discovery of new treatments for cancer patients.  While billions of dollars continue to be spent on researching and developing new cancer therapies, their success rates in clinical trials are not improving.  Imagine a human tumor on the laboratory bench that responds to new therapies as if it were in the human body.  That is what our science is capable of achieving," said Dr. Wamhoff.

HemoShear's success in this initial stage of tumor system development will lead to development of other cancer tumor systems, to systems that replicate metastasis and potentially to new treatments for patient-specific tumors. 

"This is HemoShear's third major area of SBIR funding from separate divisions of the NIH in three years.  We are grateful for the strong support of NIH and the scientific community.  We believe that HemoShear science will yield safer and more effective therapies while avoiding costly new drug failures," said Jim Powers, HemoShear's CEO.

About HemoShear

HemoShear has developed the only technology of its kind that accurately replicates human organ system and disease biology in the laboratory.  HemoShear science is rapidly being adopted by leading pharmaceutical and biotechnology companies to make better decisions and select drug candidates with superior efficacy and safety profiles.  Working in partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making and reduce risk of costly failures.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemoShear Hires Industry Business Development Veteran Vincent Aurentz as Chief Business Officer
2. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
3. HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
4. Cato Research Presents at Korea-Maryland, USA BIO EXPO, Drug Development Process and Regulatory Approaches
5. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
6. Tunisia Hosts First African Summer School on Optics and Applications to Sustainable Development
7. Rancho BioSciences Will Present the Accelerated Cure Project Multiple Sclerosis Data Curation White Paper at the tranSMART Fall Developers Meeting, Paris, November 5-7
8. Clinical Research Site-Expert Johan Karlberg to Lead ACRES Global Network Development
9. Global Sports Development's Symposium on Doping Deepens the Anti-Doping Discussion
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Biomarker Challenges in Biosimilar Drug Development, New Life Science Webinar Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... 09, 2017 , ... The Giving Tree Wellness Center announces ... needs of consumers who are incorporating medical marijuana into their wellness and health ... As operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):